Eli Rosenberg
Eli S. Rosenberg, PhD
University at Albany School of Public Health, SUNY, Department of Epidemiology and Biostatistics - Associate Professor
Emory University Rollins School of Public Health, Department of Epidemiology and PRISM Health - Adjunct Associate Professor
PhD, Epidemiology, Emory University Rollins School of Public Health
BS, Biometry and Statistics, Cornell University
Research Interests
HIV, HCV, STI epidemiology among PWID and MSM, Surveillance methods, Statistical modeling, Dynamic modeling
Eli Rosenberg is an associate professor in the Department of Epidemiology and Biostatistics at University at Albany School of Public Health. His research centers on applied and analytic epidemiologic studies that address current public health challenges in HIV, STI, viral hepatitis, and Zika surveillance, prevention, and social determinants. He has specifically focused on sexual and racial minorities, persons who inject drugs, and the infectious disease disparities they face, with considerable effort spent on cohort and modeling studies. Specific methodological interests include surveillance methods, statistical and network modeling, causal inference methods, and development of software to support research studies. This work has occurred across a diverse portfolio of projects supported by NIH, CDC, and the NYS Department of Health.
Principal Investigator, Estimating the Population Size of Persons Who Inject Drugs in New York. Active
Principal Investigator, Modeling HIV, Viral Hepatitis, STI, and TB to Improve Public Health – CAMP 2.0: The Coalition for Applied Modeling for Prevention. Active
Principal Investigator, Research to Inform Hepatitis C Elimination Strategies in New York State. Completed


Rosenthal EM, Patterson W, Chicoine J, Dorabawila V, Adamashvili N, Rajulu DT, Rosenberg ES, Tesoriero JM (2023).
COVID-19 vaccination and hospitalization among persons living with diagnosed HIV in New York State
Journal of Acquired Immune Deficiency Syndromes, 93 (2), 92-100. doi: 10.1097/QAI.0000000000003177. PMCID: PMC10179975.

Rosenberg ES, Dorabawila V, Hart-Malloy R, Anderson BJ, Miranda W, O’Donnell T, Gonzalez CJ, Abrego M, DelBarba C, Tice CJ, McGarry C, Mitchell EC, Boulais M, Backenson B, Kharfen M, McDonald J, Bauer UE (2023).
Effectiveness of JYNNEOS vaccine against diagnosed mpox infection – New York, 2022
MMWR Morbidity and Mortality Weekly Report, 72 (20), 559-563. doi: 10.15585/mmwr.mm7220a4. PMCID: PMC10205166.

Bradley H, Hall E, Asher A, Furukawa N, Jones CM, Shealey J, Buchacz K, Handanagic S, Crepaz N, Rosenberg ES (2023).
Estimated number of people who inject drugs in the United States
Clinical Infectious Diseases, 76 (1), 96-102. doi: 10.1093/cid/ciac543. PMCID: PMC10202436.

Bradley H, Austin C, Allen ST, Asher A, Bartholomew TS, Board A, Borquez A, Buchacz K, Carter A, Cooper HLF, Feinberg J, Furukawa N, Genberg B, Gorbach PM, Hagan H, Huriaux E, Hurley H, Luisi N, Martin NK, Rosenberg ES, Strathdee SA, Des Jarlais DC (2022).
A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic
International Journal of Drug Policy, 110, 103889. doi: 10.1016/j.drugpo.2022.103889. PMCID: PMC9574463.

Hall EW, Gounder P, Angles J, Nelson NP, Rosenberg ES, Weng MK (2022).
Evaluating the cost-effectiveness of hepatitis B vaccination strategies in high-impact settings for adults
Journal of Viral Hepatitis, 19 (12), 1115-1126. doi: 10.1111/jvh.13759.


Bradley H, Rosenberg ES, Holtgrave DR (2019).
Data-driven goals for curbing the U.S. HIV epidemic by 2030
AIDS and Behavior, 23 (3), 557-563. doi: 10.1007/s10461-019-02442-7.

Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, Dietz P, Mermin J, Ryerson AB (2018).
Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016
JAMA Network Open, 1 (8), e186371. doi: 10.1001/jamanetworkopen.2018.6371. PMCID: PMC6324373.

Dr. Rosenberg's Google Scholar Profile